CB 2782
/ Vertex
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 15, 2022
"$CBIO Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology https://t.co/OmDEqHHOXH"
(@stock_titan)
Dry Age-related Macular Degeneration • Ophthalmology
December 23, 2019
"Biogen pays $15 million to obtain rights to exclusively develop and commercialize Catalyst's CB-2782-PEG for geographic atrophy-associated dry AMD"
(@Cortellis)
1 to 2
Of
2
Go to page
1